Brokerages Set CVRx, Inc. (NASDAQ:CVRX) PT at $17.00

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $17.00.

A number of equities analysts have recently commented on CVRX shares. Piper Sandler restated an "overweight" rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a report on Wednesday, October 30th. Cantor Fitzgerald reissued an "overweight" rating and issued a $14.00 price objective on shares of CVRx in a research report on Wednesday, October 23rd. William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Lake Street Capital increased their price target on CVRx from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their target price on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, January 17th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Jane Street Group LLC boosted its holdings in CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock worth $168,000 after purchasing an additional 5,053 shares during the period. Geode Capital Management LLC boosted its holdings in shares of CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock valued at $2,600,000 after buying an additional 6,443 shares during the period. Calamos Advisors LLC bought a new stake in shares of CVRx during the 4th quarter valued at about $134,000. SG Americas Securities LLC acquired a new stake in CVRx during the third quarter worth about $108,000. Finally, Barclays PLC raised its stake in CVRx by 312.5% during the third quarter. Barclays PLC now owns 19,067 shares of the company's stock worth $169,000 after acquiring an additional 14,445 shares during the period. Institutional investors and hedge funds own 75.27% of the company's stock.

CVRx Trading Down 1.9 %

Shares of CVRX stock traded down $0.32 during trading hours on Friday, hitting $16.49. 43,120 shares of the company were exchanged, compared to its average volume of 259,465. CVRx has a 1 year low of $6.40 and a 1 year high of $26.55. The firm has a fifty day moving average of $14.67 and a 200 day moving average of $11.55. The firm has a market cap of $400.05 million, a PE ratio of -6.15 and a beta of 1.26. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The company had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. During the same quarter last year, the business earned ($0.43) EPS. Analysts expect that CVRx will post -2.61 earnings per share for the current year.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.